Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | POLA1 | P09884 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aphidicolin SCHEMBL16610406 | 0.84 | POLA1 (1.00) | LMNAPOLA1HTTRECQLSMN1; SMN2 | |
| Aphidicolin SCHEMBL183956 | 0.84 | POLA1 (1.00) | LMNAPOLA1HTTRECQLSMN1; SMN2 | |
| Aphidicolin SCHEMBL8763668 | 0.84 | POLA1 (1.00) | LMNAPOLA1HTTRECQLSMN1; SMN2 | |
| Aphidicolin SCHEMBL14667945 | 0.84 | POLA1 (1.00) | LMNAPOLA1HTTRECQLSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29351943 | 0.71 | CYP2C19 (0.98) | LMNAPOLA1HTTRECQLSMN1; SMN2 | |
| SCHEMBL29483361 | 0.70 | LMNA (0.56) | LMNAPOLA1HTTRECQLSMN1; SMN2 | |
| SCHEMBL15747 | 0.65 | CYP2C19 (0.70) | LMNAPOLA1HTTRECQLSMN1; SMN2 | |
| Stemodin SCHEMBL15978379 | 0.64 | LMNA (0.47) | LMNAPOLA1HTTRECQLSMN1; SMN2 | |
| SCHEMBL1701699 | 0.57 | LMNA (0.40) | LMNAPOLA1HTTRECQLSMN1; SMN2 | |
| SCHEMBL24834680 | 0.54 | HSD11B1 (0.67) | LMNAPOLA1HTTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150093371-A1 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE | Humanitas Technology, LLC (US) | 2015-04-02 | — | — | US | disclosed |
| US-20130012470-A1 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE | Humanitas Technology, LLC (US) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012470-A1 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE | EIF2AK2, MAVS, DHX36 | LMNA 2308/4885POLA1 1619/4885HTT 3404/4885 |
| US-20150093371-A1 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE | DDX5, MAVS, EIF2AK2 | LMNA 3080/4885POLA1 1649/4885HTT 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.